Overview

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
An open label phase 3 study
Phase:
Phase 3
Details
Lead Sponsor:
Sun Pharma Global FZE
Sun Pharmaceutical Industries Limited